Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Dakin

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Nature Communications|May 16, 2025
Inhibiting peptidylarginine deiminases (PAD1-4) by targeting a Ca<sup>2+</sup> dependent allosteric binding siteLeslie A Dakin, Li Xing, Justin Hall, et al.
Scientific Reports|August 17, 2016
Binding site elucidation and structure guided design of macrocyclic IL-17A antagonistsShenping Liu, Leslie A Dakin, Li Xing, et al.
Nature Communications|January 2, 2025
Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney diseaseBrandon Zimmerman, Leslie A Dakin, Anne Fortier, et al.
Journal of Medicinal Chemistry|May 25, 2016
Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 BromodomainsTerry D Crawford, Vickie Tsui, E Megan Flynn, et al.
ACS Medicinal Chemistry Letters|May 19, 2016
Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)Alexander M Taylor, Alexandre Côté, Michael C Hewitt, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Nature Communications|May 16, 2025
Inhibiting peptidylarginine deiminases (PAD1-4) by targeting a Ca<sup>2+</sup> dependent allosteric binding siteLeslie A Dakin, Li Xing, Justin Hall, et al.
Scientific Reports|August 17, 2016
Binding site elucidation and structure guided design of macrocyclic IL-17A antagonistsShenping Liu, Leslie A Dakin, Li Xing, et al.
Nature Communications|January 2, 2025
Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney diseaseBrandon Zimmerman, Leslie A Dakin, Anne Fortier, et al.
Journal of Medicinal Chemistry|May 25, 2016
Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 BromodomainsTerry D Crawford, Vickie Tsui, E Megan Flynn, et al.
ACS Medicinal Chemistry Letters|May 19, 2016
Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)Alexander M Taylor, Alexandre Côté, Michael C Hewitt, et al.
Pageof 8